somatostatin Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (2)

Phase 1 (1)
Phase 2 (1)

Interventional (2)

Jules Bordet Institute (1)
Vastra Gotaland Region (1)

No (2)

No (2)

Adult (18+) (2)

I am/have/had

I am/have/hadmeasurable disease

I am/have/hadneuroendocrine tumors

I am/have/hadhysterectomy

I am/have/hadki-67

I am/have/hadcomplete resection

I am/have/hadplatelet count

I am/have/hadbilateral salpingectomy

I am/have/hadserum pregnancy test

I am/have/hadneuroendocrine tumor

I am/have/hadrenal function

I am/have/hadfdg pet/ct

I am/have/hadoophorectomy

I am/have/hadmeningioma

I am/have/hadfdg-pet

I am/have/hadmetastasis

I am/have/hadprogressive disease

I am/have/hadliver metastasis

I am/have/hadbone marrow procedure

I am/have/hadthymoma

I am/have/hadluteinizing hormone

added new label for I am/have/had

more

I am looking for

I am looking forsomatostatin

I am looking fordotatate

I am looking forparp inhibitor

I am looking forfollicle-stimulating hormone

I am looking forfollicle stimulating hormone

I am looking forluteinizing hormone

I am looking fordaratumumab

I am looking forolaparib

I am looking forbortezomib

I am looking fortetraxetan

I am looking fordota-tate

I am looking forcarfilzomib

added new label for I am looking for

more

Advanced Filters

Loading...

Found 2 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Neurology
Recruiting

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET. The combination of a PARP inhibitor that will specifically target the repair mechanism, with ionising radiation causing SSB's might overcome the repair dependent …

measurable disease

neuroendocrine tumors

dotatate

hysterectomy

ki-67

0 views
16 Feb, 2024
1 location

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Family Medicine
Recruiting

Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients

This study wil assess somatostatin receptor (SSTR) expression via the uptake of Gallium-68 labelled DOTA-conjugated SSTR targeting peptide using PET/CT imaging in multiple myeloma lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory and relapsing mutiple myeloma using the Lutetium-177 radiolabelled targeting …

measurable disease

carfilzomib

fdg pet/ct

pet/ct scan

renal function

0 views
05 Aug, 2020

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.